Ersodetug efficacy and safety
4 evidence topics · 19 sources
Summary: upLIFT phase 3 trial, preliminary results
- upLIFT is a single-arm, open-label trial in 16 adults with uncontrolled hypoglycemia caused by tumor hyperinsulinism (12 with malignant insulinomas and 4 with non-islet cell tumors) who receive ersodetug 9 mg/kg weekly for 8 weeks as an add-on to standard of care. The primary endpoint is the proportion of participants who achieve at least a 50% reduction from baseline in glucose infusion rate within the 8-week pivotal phase; statistical significance requires the lower bound of the 95% confidence interval to exceed 30%, which equates to at least 9 responders.
- In preliminary results announced on 13 November 2026, 13 participants had met the responder criterion, including 12 who also achieved complete discontinuation of IV glucose. Three participants remained in the pivotal period, including 2 who had not yet met the criterion. One participant with stage 4 metastatic colon cancer and ECOG 4 status withdrew to home hospice and died one week later from cancer progression, and is counted as a non-responder.
- The manufacturer states that the results are preliminary and may change upon completion of the study, and reports no drug-related safety findings attributed to ersodetug in the pivotal and extension phases.
Summary: expanded access in tumor hyperinsulinism
- A retrospective case series reports 8 adults with refractory hypoglycemia (metastatic insulinoma, 7; cervical neuroendocrine carcinoma, 1) treated with ersodetug under compassionate use. Six of 7 individuals on parenteral glucose discontinued it within 90 days (median, 4.5 days). Percent time below 70 mg/dL by continuous glucose monitoring fell from a mean of 12.4% to 8.0% (median absolute change −3.8%; 90% CI, −8.2 to −1.1), and the mean number of antihypoglycemic therapies fell from 3.8 to 1.6. All 6 hospitalized individuals were discharged (median, 9 days; range, 1-84), and 7 proceeded to tumor-directed therapy within 8 weeks. The authors report nominal P-values with no prespecified hypothesis testing.
- Company presentations of 9 patients report that 7 of 8 patients receiving parenteral glucose at baseline achieved at least a 50% reduction, and that 75% of patients receiving IV dextrose or parenteral nutrition discontinued it completely.
- No drug-related serious adverse events occurred in the case series; 3 of 8 individuals had serious adverse events, all attributed to tumor progression or tumor-directed therapies. Six individuals died, with tumor progression and sepsis cited as causes.
Summary: supporting trials in congenital hyperinsulinism and healthy volunteers
- sunRIZE, a randomized, double-blind, placebo-controlled phase 3 trial in congenital hyperinsulinism, did not meet its primary endpoint: weekly hypoglycemia events by self-monitored blood glucose fell by approximately 45% at 10 mg/kg and by 40% with placebo. It did not meet its key secondary endpoint: percent time in hypoglycemia by continuous glucose monitoring fell by approximately 25% at 10 mg/kg and rose by approximately 5% with placebo (congress presentation: −32%, p=0.30). After reviewing the data, the FDA encouraged a pre-BLA meeting for congenital hyperinsulinism and did not opine on approvability; the manufacturer states that the FDA may require another study similar to sunRIZE, and that it has asked the FDA whether the sunRIZE results will affect the assessment of ersodetug in tumor hyperinsulinism.
- RIZE, an open-label phase 2 study in 23 participants with congenital hyperinsulinism aged 2 years and older who received 3 to 9 mg/kg for 8 weeks, was not powered for its endpoints. Hypoglycemia events by self-monitored blood glucose and time in hypoglycemia by continuous glucose monitoring improved from baseline by medians of 59% and 54% (p < 0.001) across pooled doses; the improvements did not translate to a similar improvement in time in range (70–180 mg/dL), the registry primary endpoint.
- In 29 healthy adult males given single ascending doses, ersodetug showed dose-proportional pharmacokinetics with a half-life of 21 days, was well tolerated, and reduced insulin sensitivity in a dose-dependent manner.
Summary: safety across the clinical trials
- Ersodetug has no prescribing information. Serious hypersensitivity reactions led to early discontinuation in 2 sunRIZE participants (topline release); a later congress presentation reports hypersensitivity leading to discontinuation in 3 participants, 2 with serious allergic reactions including anaphylaxis, and an overall incidence of approximately 2% across the clinical trials.
- Hypertrichosis was reported in about 35% (congress presentation) or 36% (n=14, January 2026 presentation) of ersodetug-treated sunRIZE participants, was described as mild and not dose-dependent, and led to discontinuation in 1 participant. Adverse events occurred in about 90% of sunRIZE participants at a comparable rate across groups. No clinically relevant hyperglycemia and no hepatic signal by liver enzymes or ultrasound were reported.
- In RIZE there were no deaths, adverse drug reactions, or discontinuations due to adverse events; 3 serious adverse events were judged unrelated to study drug, and 1 of 23 participants had low-titer anti-drug antibodies.
- Liver findings in Sprague Dawley rats led to partial clinical holds on the congenital hyperinsulinism studies; the FDA removed the holds in September 2024, concluding that the toxicity is likely strain-specific and not otherwise relevant to humans. No drug interaction, pregnancy, or lactation data were identified.